Lärkberget

2.42 SEK

-1.63 %

Less than 1K followers

LARK

First North Stockholm

Investment

Financials

Overview

Financials & Estimates

Ownership

-1.63 %

+1.68 %

+7.08 %

+2.98 %

-0.82 %

-5.47 %

-71.55 %

-81.63 %

-97.48 %

Lärkberget is a Swedish investment company. The company's main areas of activity are direct investments in low-risk instruments, investments in listed shares, funds and other liquid asset classes, as well as participation in bridge loans and guarantee commitments, investments in unlisted profitable companies, and reverse acquisitions. Lärkberget is headquartered in Stockholm.

Market cap

47.92M SEK

Turnover

211.09K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

7.5

2026

General meeting '26

20.8

2026

Interim report Q2'26

11.2

2027

Annual report '26

All

Press releases

3rd party

ShowingAll content types

Third party research2/14/2025, 10:01 AM

CombiGene: Making place for new ventures - VH Corp

• All research activities discontinued • Notice of an extraordinary general meeting on February 20, 2025 • Q&A with chairman Luca Di Stefano After a strategic evaluation of its operations, CombiGene’s board decided to discontinue all research activities...

Press release2/14/2025, 8:21 AM

Västra Hamnen Market Focus: CombiGene: Making place for new ventures

Regulatory press release2/14/2025, 7:50 AM

Year-end report January-December 2024 CombiGene AB (Publ)

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release1/28/2025, 7:30 AM

Discontinuation of research activities

Regulatory press release1/9/2025, 3:00 PM

Stockslätten AB acquires all shares from Strategic Partners A/S

Regulatory press release1/9/2025, 2:50 PM

Clarification regarding the management's role during the restructuring period

Regulatory press release1/9/2025, 7:45 AM

CombiGene initiates restructuring as part of strategic review to maximize shareholder value

Regulatory press release12/17/2024, 1:30 PM

CombiGene AB (publ): Nominating committee

Regulatory press release12/10/2024, 1:50 PM

Bulletin from the Extraordinary General Meeting of CombiGene AB (publ)

Press release12/2/2024, 2:00 PM

CombiGene conducts Extraordinary General Meeting

Regulatory press release11/14/2024, 2:40 PM

Shareholders’ proposal for election of Board of Directors

Third party research11/11/2024, 1:39 PM

CombiGene: Strategic consequences after CG01 - VH Corp

* Implementing cost savings and new priorities * New propositions from the main shareholder * Our revised fair value estimate is SEK 8.27 (12.19) per share In our previous analysis, CombiGene was focused on outlicensing the epilepsy project CG01 again...

Regulatory press release11/8/2024, 8:00 AM

Interim report January – September 2024 for CombiGene AB (publ)

Regulatory press release11/1/2024, 9:00 AM

NOTICE OF EXTRAORDINARY GENERAL MEETING IN COMBIGENE AB (PUBL)

Regulatory press release10/31/2024, 5:00 PM

The Board of Directors of CombiGene has received proposals from the Company’s largest shareholder for the Extraordinary General Meeting intended to be convened

Press release10/30/2024, 8:07 AM

BioStock: CombiGene implements cost savings

Third party research10/30/2024, 6:21 AM

CombiGene: New priorities after strategic decision - VH Corp

* Terminating the CG01 programme * Implementing cost savings to prolong the financial runway * Our fair value estimate is under review Recently, CombiGene announced new priorities in its pipeline and a cost saving programme to prolong its financial runway...

Press release10/29/2024, 3:15 PM

Västra Hamnen Market Focus: CombiGene: New priorities after strategic decision

Regulatory press release10/28/2024, 7:50 AM

CombiGene Initiates Measures to Extend Liquidity Horizon by Sharpening Strategic Focus on Gene Therapy, Prioritizing Pipeline Assets, and Implementing a Cost Reduction Program

Regulatory press release9/30/2024, 11:15 AM

CombiGene announces new preclinical research results in the epilepsy project

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.